Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-β-arabinofuranosylcytosine

European Journal of Medicinal Chemistry

Volumn 44, Issue 9, 2009, Pages 3596-3600

  Liu, Boyang ^a   Cui, Chunying ^a   Duan, Wei ^a   Zhao, Ming ^a   Peng, Shiqi ^a   Wang, Lili ^a,b   Liu, Hu ^a,b   Cui, Guohui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

Anti tumor; Ara C; Ara C derivatives; Hela cells; HL 60 cells; Leukemia

Indexed keywords

AMINO ACID DERIVATIVE; ANTINEOPLASTIC AGENT; ARGININE; CYTARABINE; CYTARABINE DERIVATIVE; CYTARABINE N4 FATTY ACID DERIVATIVE; FATTY ACID DERIVATIVE; GLUTAMIC ACID; METHIONINE; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; LIPOPHILICITY; MELTING POINT; MOUSE; NONHUMAN; OPTICAL ROTATION; PARTITION COEFFICIENT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTARABINE; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HL-60 CELLS; HUMANS; LIPIDS; MICE; SARCOMA 180; SOLUBILITY;

EID: 67650450487     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.02.028     Document Type: Article

References (20)

1. Miura S., and Izuta S. Curr. Drug Targets 5 (2004) 191-195
2. Grant S. Ara-C. Adv. Cancer Res. 72 (1998) 197-233
3. Bergman A., Pinedo H., Jongsma A., Brouwer M., Haperen V., Veerman G., Leyva A., Eriksson S., and Peters G. Biochem. Pharmacol. 57 (1999) 397-406
4. Ye Q. J. Clin. Pediatr. 21 (2003) 586-592
5. Schabel F., Skipper H., Trader M., Brockman R., Laster W., Corbbett T., and Riswold D. Med. Pediatr. Oncol. 10 (1982) 125-148
6. Skipper H., Schabel J., and Lloyd H. Semin. Hematol. 15 (1978) 207-219
7. Curt G., Clendininn N., and Chabner B. Cancer Treat. Rep. 68 (1984) 87-99
8. Divakar K., and Reese C. J. Chem. Soc., Perkin Trans. 1 (1982) 1171-1176
9. Chabner B. In: DeVita V., Hellman S., and Rosenberg S. (Eds). Cancer: Principles and Practice of Oncology (1993), JB Lippincott Co., Philadelphia 365-369
10. Yuji T., Tomoaki I., Fujisaki J., Seiji S., and Akira K. Chem. Pharm. Bull. 36 (1988) 3574-3583
11. Fadl T., Hasegawa T., Youssef A., Farag H., Omar F., and Kawaguchi T. Pharmazie 50 (1995) 382-387
12. Yun H., Charles D., Wu D., Maksim R., and Richard B. J. Controlled Release 79 (2002) 41-53
13. Wang J., and Li S. Qingdao Med. J. 21 (1999) 85-89
14. Wechter W., Gish D., Greig M., Gray G., Moxley T., Kuentzel S., Gray L., Gibbons A., Griffin R., and Neil G. J. Med. Chem. 19 (1976) 1013-1017
15. Balajthy Z., Aradi J., Kiss I., and Elodi P. J. Med. Chem. 35 (1992) 3344-3349
16. You Q. In: You Q. (Ed). Medicinal Chemistry (2004), Chemical Industry Press, Beijing 538-541
17. Aoshima M., Tsukagoshi S., Sakurai Y., Ohishi J., Ishida T., and Kobayashi H. Cancer Res. 36 (1976) 2726-2732
18. Bergman A., Kuiper C., Voorn D., Comijn E., Myhren F., Sandvold M., Hendriks H., and Peters G. Biochem. Pharmacol. 67 (2004) 503-511
19. Aoshima M., Tsukagoshi S., Sakurai Y., Oh-Ishi J., Ishida T., and Kobayashi H. Cancer Res. 37 (1977) 2481-2486
20. Ernest K., Miroslav P., Verheyden P., and John G. J. Med. Chem. 19 (1976) 667-674